[unable to retrieve full-text content] Results point to Enspryng® (Satralizumab) as effective in blocking IL-6 receptor and MOGAD-related inflammation. WASHINGTON, DC, UNITED STATES, April 21, 2026 /⁨EINPresswire.com⁩/ -- The MOG Project is thrilled to share its excitement on the …

read more